Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,550,700.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the transaction, the director now owns 2,056,931 shares of the company’s stock, valued at approximately $212,645,526.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $107.12, for a total value of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total transaction of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total transaction of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00.

Moderna Stock Performance

Moderna stock traded down $0.59 during trading hours on Friday, reaching $101.41. 2,608,152 shares of the stock were exchanged, compared to its average volume of 4,160,939. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $144.43. The stock has a market cap of $38.83 billion, a P/E ratio of -8.16 and a beta of 1.62. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The firm’s 50 day moving average is $100.35 and its 200 day moving average is $93.65.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business’s revenue was down 44.9% compared to the same quarter last year. During the same period in the previous year, the business posted $3.61 earnings per share. Analysts predict that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the subject of several research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Royal Bank of Canada reissued an “outperform” rating and set a $125.00 target price on shares of Moderna in a report on Thursday, March 28th. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target on the stock in a research note on Tuesday, January 2nd. HSBC reissued a “reduce” rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Finally, William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and a consensus price target of $126.49.

Hedge Funds Weigh In On Moderna

Large investors have recently modified their holdings of the business. First Trust Direct Indexing L.P. grew its stake in shares of Moderna by 31.8% during the 1st quarter. First Trust Direct Indexing L.P. now owns 4,924 shares of the company’s stock worth $525,000 after purchasing an additional 1,188 shares during the period. DMC Group LLC grew its position in Moderna by 11.3% during the first quarter. DMC Group LLC now owns 8,586 shares of the company’s stock worth $915,000 after buying an additional 870 shares during the period. Abundance Wealth Counselors grew its position in Moderna by 20.7% during the first quarter. Abundance Wealth Counselors now owns 4,863 shares of the company’s stock worth $518,000 after buying an additional 835 shares during the period. Westside Investment Management Inc. purchased a new position in Moderna in the first quarter valued at about $32,000. Finally, Norden Group LLC acquired a new stake in shares of Moderna during the 1st quarter valued at approximately $1,337,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.